We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
America Great Health (CE) | USOTC:AAGH | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0001 | 0.00 | 00:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
| | |
(Commission File Number) | (IRS Employer Identification No.) | |
| ||
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a material definitive agreement
On September 20, 2024, the International Institute of Great Health, Inc. (the "Company"), a wholly owned subsidiary of America Great Health, entered into a Technology Contract for Commissioned Development (the "Contract") with Yunan Yunchi Xiai Trading Co. Ltd., a Chinese company ("Yunchi"). Under the Contract, Yunchi has engaged the Company to provide specialized technical development for its sea cucumber ion peptide project, and will compensate the Company for these services. The development involves the Company's proprietary, patented protein skin surface ion modification, transformation technology, which will be applied to Yunchi's existing sea cucumber raw materials. This process will not only preserve the original properties of the materials but also add the ability to inhibit the growth of cancer cells in vitro.
According to the Contract, the technology development will take place in a laboratory in the United States, while the experimental base will be in China. The development period is set for three (3) months.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
AMERICA GREAT HEALTH
Date: October 08, 2024
By: /s/ Mike Wang
Name: Mike Wang
Title: President
Document And Entity Information |
Oct. 08, 2024 |
---|---|
Document Information Line Items | |
Entity Registrant Name | America Great Health |
Document Type | 8-K |
Amendment Flag | false |
Entity Central Index Key | 0001098009 |
Document Period End Date | Oct. 08, 2024 |
Entity Emerging Growth Company | false |
Entity Incorporation, State or Country Code | WY |
Entity File Number | 0-27873 |
Entity Tax Identification Number | 98-0178621 |
Entity Address, Address Line One | 1609 W Valley Blvd., #338, |
Entity Address, City or Town | Alhambra |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 91803 |
City Area Code | (626) |
Local Phone Number | 576-1299 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | N/A |
No Trading Symbol Flag | true |
1 Year America Great Health (CE) Chart |
1 Month America Great Health (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions